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We have measured plasma progranulin and interleukin-6 in 230 patients with frontotemporal lobar
degeneration (FTLD), 104 patients with Alzheimer’s disease, and 161 control subjects. We have replicated
previous ﬁndings of decreased levels of progranulin protein in FTLD because of mutations in GRN and
show this is not observed in FTLD cases because of other causes. interleukin-6 levels were increased in
FTLD overall, but these did not discriminate between clinical and genetic subtypes.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Frontotemporal lobar degeneration (FTLD) is the second most
common cause of dementia in people younger than 65 years. The
prototypical clinical syndromes are behavioral variant fronto-
temporal dementia, progressive nonﬂuent aphasia (PNFA), and se-
mantic dementia (SD). Pathologically, about half of the cases show
an accumulation of hyperphosphorylated tau proteins, some being
associated with mutations in MAPT. Most others show an accu-
mulation of the transactive DNA-binding protein, TDP-43, inherited
cases being associated with mutations in progranulin (GRN) or
hexanucleotide expansions in C9ORF72. However, when no gene
mutation is known, it is not possible to accurately predict the un-
derlying histology. A valid biological marker would not only help in
formulating diagnosis, but could also serve as a potential index of
treatment efﬁcacy. Some progress has been made in this regard.
Reductions in plasma levels of progranulin (PGRN) have been
associated with GRN mutations (Finch et al., 2009; Ghidoni et al.,
2008; Hsiung et al., 2011; Sleegers et al., 2009), and patients with
FTLD have been reported to show increased cerebrospinal ﬂuid or
plasma levels of proinﬂammatory mediators (Sjorgen et al., 2004;
Galimberti et al., 2006; Bossu et al., 2011).t, Department of Neurology,
al Foundation Trust, Salford
) 161 206 0388.
M.A. Mann).
Inc. This is an open access articleWe therefore measured plasma PGRN and interleukin-6 (IL-6) in
patients with FTLD, Alzheimer’s disease (AD), and healthy (spouse)
control subjects to ascertain whether levels of these have potential
to discriminate patients with FTLD from other neurodegenerative
disorders (AD) and healthy individuals, and also whether they can
differentiate between clinical, neurohistologic, and genetic sub-
types of FTLD.We investigated 230 patients with FTLD,104 patients
with AD, and 161 healthy control subjects (Table 1). Patients with
FTLD fulﬁlled current clinical diagnostic criteria (Harris et al., 2013),
and clinical diagnosis of AD was consistent with International
Consensus Clinical Criteria (McKhann et al., 1984). Of patients with
FTLD, 117 had behavioral variant frontotemporal dementia, 31 had
FTDþMND, 35 had SD, 42 had PNFA, and 5 had progressive apraxia
(PAX) (Table 1). Ten patients with FTLD bore mutations in GRN, one
had a MAPT mutation, and 13 bore hexanucleotide repeat expan-
sions in C9ORF72. The control subjects were spouses of the patients.
They were neither related to each other nor to the patients (except
throughmarriage). The 3 diagnostic groups did not differ as tomean
age at onset or duration of illness when sampled. Within the FTLD
group, age at onset was later in patients with FTDþMND and PNFA
than those with FTD, and age when sampled was later in patients
with PNFA than those with FTD. Duration of illness when sampled
was longer in patients with SD than those with FTD þ MND. There
were no signiﬁcant differences for age at onset, age when sampled,
and duration of illness when sampled between patients with the
GRN mutation, patients with the C9ORF72 mutation andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Mean (SD) age at onset, age when sampled, current duration of illness, PGRN and IL-6 levels for patients with FTLD, both overall and when stratiﬁed according to clinical or
genetic status, AD, and control subjects
Diagnostic group Age at onset (y) Age when sampled (y) Duration (y) PGRN (ng/mL) IL-6 (pg/mL)
bvFTD (n ¼ 117) 58.6  8.9 62.5  8.8 4.0  3.0 54.7  15.7 4.4  3.4****
bvFTD þ MND (n ¼ 31) 64.4  8.2* 67.2  8.3 2.7  1.5 56.6  15.7 4.7  1.8
SD (n ¼ 35) 60.5  6.0 65.7  6.8 5.0  3.0** 55.5  13.6 4.3  1.1
PNFA (n ¼ 42) 65.2  7.0* 68.6  7.1* 3.4  2.1 49.6  13.4 3.8  1.9
PAX (n ¼ 5) 66.2  14.7 69.7  14.2 3.5  1.9 49.0  13.5 4.8  1.1
All FTLD (n ¼ 230) 61.1  8.7 64.9  8.7 3.9  2.7 52.1  17.1 4.3  2.6
MAPTþ (n ¼ 1) 58 58.9 0.9 39.2 1.9
GRNþ (n ¼ 10) 59.8  4.0 62.1  4.7 2.4  1.0 11.1  5.0*** 3.9  0.9
C9ORF72 þ (n ¼ 13) 59.0  8.2 62.7  10.0 4.6  4.8 61.0  18.0 4.0  0.9
Nonmutation bearers (n ¼ 206) 61.2  8.9 65.2  8.7 3.9  2.6 53.5  14.6 4.3  2.8
AD (n ¼ 104) 62.3  8.3 66.2  8.1 3.7  1.8 51.9  12.6 3.1  2.5
Controls (n ¼ 161) NA 65.1  9.4 NA 53.7  13.7 3.5  3.4
Key: bvFTD, behavioral variant frontotemporal dementia; FTLD, frontotemporal lobar degeneration; IL-6, interleukin-6; NA, not applicable; PGRN, progranulin; SD, semantic
dementia.
* p < 0.006 compared with bvFTD.
** p < 0.01 compared with bvFTD þ MND.
*** p < 0.001 compared with C9ORF72þ and nonmutation bearers.
**** p < 0.018 and 0.001 compared with AD and controls, respectively.
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with informed consent and full ethical approval. Plasma was sepa-
rated routinely and stored at 80 C until required for assay. PGRN
and IL-6 were assayed in triplicate by enzyme-linked immunosor-
bent assay using speciﬁc high sensitivity commercially available kits
(DPGRNO kit, R&D Systems for PGRN, Quantikine H&S kit for IL-6) in
accordance with the manufacturer’s recommendations. The limits
of detection were 0.17 ng/mL for PGRN and 0.20 pg/mL for IL-6.
PGRN was measured on all subjects, whereas IL-6 measures were
performed on all except 2 of the FTLD patients, all except 2 of the AD
patients and all except 3 of the control subjects, where insufﬁcient
sample remained to complete both assays. DNAwas extracted fromFig. 1. Boxplots formeasures of plasma PGRN (A-C) and IL-6 (D-F) levels for Frontotemporal Lo
and for FTLD groups stratiﬁed by clinical presentation into those with Frontotemporal demen
gressive non-ﬂuent Aphasia (PNFA) and Progressive Apraxia (PAX) (B,E), and by genetics intowhite blood cells separated from whole blood by routine centrifu-
gation. Screening for mutations in MAPT, GRN, and expansions in
C9ORF72 had already been performed on all subjects. Most of GRN
rs5848 genotypes were obtained using Sequenom Mass array gen-
otyping assays using 15 ng of DNA, as per the manufacturer’s in-
structions. Additional genotypes for GRN rs5848 and TMEM106B
rs1020004, rs6966915, and rs1990622 SNPs was obtained using
Applied Biosystems assay numbers C__7452046_20, and
C__7604953_10, C_31573289_10 and C__11171598_10, respectively.
A total of 10 ng of each DNA was ampliﬁed and genotyped on the
7700 Real time PCR system. Genotype calls were made using SDS
v2.3 software (Applied Biosystems, Foster City, CA). All statisticalbar degeneration (FTLD), Alzheimer’s Disease (AD) and control groups, collectively, (A,C),
tia (FTD), FTD with Motor Neurone Disease (FTDþMND), Semantic dementia (SD), Pro-
cases with GRN mutations, expansions in C9ORF72 or no known mutation (C,F).
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to compare age at onset, age at sampling, duration of illness, PGRN
and IL-6 levels between the various clinical diagnostic and genetic
groups with post hoc testing (subject to Bonferroni correction)
when a signiﬁcantly different analysis of variance result was ob-
tained. Pearson correlation tests were used to test for correlation
between IL-6 and PGRN measures, and between each of these and
age at onset, age at sampling, and disease duration. Signiﬁcance
levels were set at p < 0.05.
Overall, there were no signiﬁcant differences in mean plasma
PGRN level between patients with FTLD, AD, or control subjects
(Fig.1A). However, mean plasma PGRN levels within the FTLD group
were signiﬁcantly lower in patients with GRNmutations than those
with C9ORF72 expansions, or nonmutation bearers (which in turn
did not differ from each other) (Table 1; Fig. 1C). Hence, the range of
values was 24.2e121.1 ng/mL (mean 53.7  13.7 ng/mL) for control
subjects, 27.4e93.9 ng/mL (mean 51.9 12.6 ng/mL) for AD subjects
and 23.7e85.0 ng/mL (52.7 14.7 ng/mL) for FTLD subjects without
GRN mutations. All FTLD patients with GRN mutations had plasma
PGRN levels below 22.0 ng/mL (range 1.1e21.0 ng/mL, mean 11.1 
5.0 ng/mL), this being below the lower conﬁdence interval for FTLD
patients without GRN mutations. There were no signiﬁcant differ-
ences in mean plasma PGRN levels according to clinical presenta-
tion (Fig. 1B). Themean plasma IL-6 level was signiﬁcantly higher in
FTLD than in AD and control subjects, the latter 2 groups not
differing signiﬁcantly (Fig. 1D). Hence, the range of values was 3.5
to 10.4 pg/mL (mean 3.5  3.4 pg/mL) for control subjects, 1.0 to
9.6 pg/mL (mean 4.4 2.7 pg/mL) for all FTLD subjects without GRN
mutations, 2.0e5.6 pg/mL (mean 3.9  0.9 pg/mL) for patients with
GRNmutations and2.2 to 7.4 pg/mL (mean 3.12.5 pg/mL) for AD
subjects. There were no signiﬁcant differences in mean plasma IL-6
levels between the various FTLD clinical (Fig. 1E) or genetic (Fig. 1F)
subgroups. There was a highly signiﬁcant correlation between
plasma PGRN and IL-6 levels in patients with FTLD, overall (r ¼
0.195, p ¼ 0.003), but not so in AD, or control subjects. There were
no signiﬁcant correlations between plasma PGRN or IL-6 levels and
age at onset in patients with FTLD (overall or stratiﬁed clinically or
genetically), AD, or in control subjects, or between IL-6 levels and
(current) duration of illness in patients with FTLD (separately or
combined, clinically or genetically) or AD. However, there was a
highly signiﬁcant positive correlation (r ¼ 0.466, p ¼ 0.006) be-
tween PGRN levels and duration of illness for FTLD group overall,
but not for any clinical or genetic subgroup, except for SD (r¼ 0.365,
p ¼ 0.037) and the nonmutational subgroups (r ¼ 0.150, p ¼ 0.034)
where this also increased with duration of illness. We examined the
effect of GRN allele status at rs5848 and TMEM106B variants
rs1020004, rs1990622, and rs6966915 on PGRN or IL-6 plasma
levels in control subjects (n ¼ 133), AD (n ¼ 82), and FTLD cases,
excluding mutations in MAPT, GRN, and C9ORF72 (n ¼ 184), but no
signiﬁcant correlations were seen either for FTLD overall or when
stratiﬁed according to clinical diagnostic or genetic subgroup (see
online Supplementary Tables 1e4).
The results of the present study clearly demonstrate that blood
levels of PGRN are greatly reduced in patients bearing GRN muta-
tions compared with others with FTLD, those with AD, or control
subjects, and therefore support previous ﬁndings (Finch et al.,
2009; Ghidoni et al., 2009; Hsiung et al., 2011; Sleegers et al.,
2009). Such observations add to the argument that measurement
of plasma PGRN can act as a relatively quick and accurate surrogate
to screen for patients bearing mutations in GRN. Interestingly, the
GRN group contained a single patient with Q415X “mutation,”
which had not been previously shown to segregate with disease or
to be pathogenic in functional assay (Baker et al., 2006). However,
present data showing low PGRN levels in the patient with this
mutation (8.0 ng/mL) would imply the mutation is indeedpathogenic. Although mean IL-6 levels are higher in FTLD than in
AD and control subjects, the differences are not sufﬁciently clear cut
as to provide a useful biomarker for FTLD either overall or according
to clinical or genetic subtype. Previously, Bossù et al. (2011) re-
ported patients with GRN mutations showed signiﬁcantly elevated
IL-6 levels compared with FTLD patients without such mutations.
However, we ﬁnd that levels in patients with GRNmutations are not
signiﬁcantly elevated. Differences in GRN mutation, patient vari-
ability and small sample sizes giving rise to chance ﬁndings are
likely responsible for such inconsistent ﬁndings. We ﬁnd a highly
signiﬁcant correlation between plasma PGRN and IL-6 levels in
patients with FTLD, but not in AD or control subjects. This ﬁnding in
FTLD is perhaps not surprising given that PGRN expression is driven
by IL-6 secretion (Frampton et al., 2012), perhaps reﬂecting
increased microglial activity especially in GRN carriers (Ahmed
et al., 2007; Cagnin et al., 2004) or in normal control subjects.
However, if so, it is curious as to why a similar association is not
seen in AD where senile plaques are heavily invested with micro-
glial cells.
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